Bone loss and fat loss are closely related in HIV patients on HAART
1 April 2003. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Conference reports
Low dose 200/100 IDV/RTV managed by TDM in substudy of co-infected patients
1 April 2003. Related: Conference reports, PK and drug interactions, Hepatitis coinfection.
12-week response predicts which HIV-HCV coinfected patients will not benefit from continued pegylated interferon plus ribavirin
1 April 2003. Related: Conference reports, Hepatitis coinfection.
Pegylated interferon associated with eye disorders
1 April 2003. Related: Conference reports, Side effects, Hepatitis coinfection.
Nevirapine resistance – the cautionary tales continue
1 April 2003. Related: Conference reports, Pregnancy, Drug resistance.
10th Conference on Retroviruses and Opportunistic Infections, 10-14 February 2003, Boston, USA
1 March 2003. Related: Conference reports.
6th International Congress on Drug Therapy in HIV Infection, 17-21 November 2002, Glasgow, UK
1 February 2003. Related: Conference reports.
Combination of three generic drugs in one pill meets bioequivalence criteria when compared with the branded drugs: Triomune vs d4T/3TC/NVP
1 February 2003. Related: Conference reports, Antiretrovirals, Treatment access.
An overview of the conference
1 February 2003. Related: Conference reports, Antiretrovirals, Weight, diabetes, metabolic complications.
Pharmacokinetic evaluation of tenofovir and enteric-coated ddI
1 February 2003. Related: Conference reports, Antiretrovirals, PK and drug interactions.
The advantages of fosamprenavir; comparing saquinavir/r to lopinavir/r; reducing viral load to <3 copies; AZT-d4T cross resistance; and rising HCV rates
1 February 2003. Related: Conference reports, Antiretrovirals, Treatment strategies, Hepatitis coinfection, Drug resistance.
Promising data regarding DermaVir for therapeutic vaccine
1 February 2003. Related: Conference reports, Basic science and immunology.
Enfuvirtide (T-20): predicting success and modelling survival benefits
1 February 2003. Related: Conference reports, Antiretrovirals, Drug resistance.
Virologic failure among treatment-naive patients taking tenofovir DF or stavudine in combination with lamivudine and efavirenz
1 February 2003. Related: Conference reports, Antiretrovirals.
Comparison of the efficacy and safety of tenofovir vs. d4T when used in combination with 3TC and efavirenz in ARV-naive patients
1 February 2003. Related: Conference reports, Antiretrovirals, Side effects, Weight, diabetes, metabolic complications.
Safety profile of tenofovir in treatment-experienced patients
1 February 2003. Related: Conference reports, Antiretrovirals, Side effects.
42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, 27-30 September 2002
13 November 2002. Related: Conference reports.
Immunology and treatment interruption data presented at the 42nd ICAAC
13 November 2002. Related: Conference reports, Treatment strategies.
Treatment interruptions may result in poor T-cell recovery in patients with nadir CD+ count <50 cells/mm3
13 November 2002. Related: Conference reports, Treatment strategies.
Treatment interruptions are safe in patients with CD4+ count between 300 to 500 cells/mm3 and viral loads lower than 70,000 copies/mL
13 November 2002. Related: Conference reports, Treatment strategies.
Topical transdermal testosterone gel offers significant clinical benefits in hypogonadal HIV-positive patients
13 November 2002. Related: Conference reports, Other news.
BMS experimental PI atazanavir shows potency comparable to NNRTI efavirenz among treatment-naïve HIV patients
13 November 2002. Related: Conference reports, Antiretrovirals.
Adverse drug reactions and lipodystrophy in children
13 November 2002. Related: Conference reports, Paediatric care, Side effects.
Study suggests Kaletra/Combivir is better tolerated PEP than Combivir/nelfinavir
13 November 2002. Related: Conference reports.
Novel approaches to the inhibition of HIV
13 November 2002. Related: Conference reports.
Lipodystrophy and adverse drug reaction data presented at the 42nd ICAAC
13 November 2002. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
4th International Workshop on Drug Reactions and Lipodystrophy in HIV Infection, San Diego, 22-25 September 2002
13 November 2002. Related: Conference reports.
Leptin, lipodystrophy and insulin resistance
13 November 2002. Related: Conference reports.
A range of treatments for facial lipoatrophy
13 November 2002. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Autopsy evidence confirms that ARVs tackle CNS lesions
13 November 2002. Related: Conference reports, Basic science and immunology.
XI International HIV Drug Resistance Workshop, Seville, 2-5 July, 2002
11 September 2002. Related: Conference reports.
Short resistance reports from Seville
11 September 2002. Related: Conference reports, Drug resistance.
New anti-HIV compounds discussed at the Seville HIV Drug Resistance Workshop and the Barcelona World AIDS Conference
11 September 2002. Related: Conference reports, Antiretrovirals.
Review of phenotypic resistance testing data presented at the XI International HIV Drug Resistance Workshop
11 September 2002. Related: Conference reports, Drug resistance.
XIV International AIDS Conference Barcelona, 7-12 July 2002
11 September 2002. Related: Conference reports.
Bill Clinton and Nelson Mandela promise to lead peer education among political leaders as world looks for $10 billion a year to fight HIV/AIDS
11 September 2002. Related: Conference reports, Treatment access.
South African activist unveils campaign to force compulsory licences
11 September 2002. Related: Conference reports, Treatment access.
MSF study shows treatment in resource-poor settings is effective
11 September 2002. Related: Conference reports, Treatment access.
‘Barcelona Declaration’ demands 2m poor people are treated in the next two years
11 September 2002. Related: Conference reports, Treatment access.
Lives were lost as experts argued the merits of care versus prevention, says Stefano Vella
11 September 2002. Related: Conference reports, Treatment access.
Peter Piot sets out the global political agenda in the fight against HIV/AIDS
11 September 2002. Related: Conference reports, Treatment access.
Health should be a right, not a commodity, and medicine must be removed from the World Trade Organisation, argues key speaker
11 September 2002. Related: Conference reports, Treatment access.
Governments must act to cut drug prices, says Kenya’s health minister
11 September 2002. Related: Conference reports, Treatment access.
Civil society had to fight for universal access to AIDS drugs in Brazil
11 September 2002. Related: Conference reports, Treatment access.
Coalitions of local NGOs can effectively demand access to medicines, reports MSF
11 September 2002. Related: Conference reports, Treatment access.
Involvement of PLWHA is key to improving access to treatments
11 September 2002. Related: Conference reports, Treatment access.
ART can successfully tackle advanced disease in resource poor settings, reports MSF
11 September 2002. Related: Conference reports, Treatment access.
Investment in treatment and care significantly reduces company health and social expenditure in Abidjan
11 September 2002. Related: Conference reports, Treatment access.
Financing the global response to the epidemic will cost $9.2 billion a year, according to one estimate
11 September 2002. Related: Conference reports, Treatment access.
The Global Fund: what, where, how much?
11 September 2002. Related: Conference reports, Treatment access.
Leading businesses spurn Global Fund
11 September 2002. Related: Conference reports, Treatment access.
14 Caribbean governments sign cut-price drugs agreement with six pharmaceutical companies
11 September 2002. Related: Conference reports, Treatment access.
Thailand offers low-cost transfer to African countries of technology for the local production of generic antiretrovirals
11 September 2002. Related: Conference reports, Treatment access.
Informal market plays a role in distributing antiretrovirals but exposes clients to risks
11 September 2002. Related: Conference reports, Treatment access.
Abacavir hypersensitivity reactions in patients who rechallenge after interruptions for reasons other than hypersensitivity
11 September 2002. Related: Conference reports, Side effects.
Prolonged CNS side-effects of efavirenz can be severe and lead to treatment discontinuation
11 September 2002. Related: Conference reports, Side effects.
Four drug regimen for infants
11 September 2002. Related: Conference reports, Paediatric care.
Study of MTCT programme finds resistance in women on two doses of monotherapy
11 September 2002. Related: Conference reports, Pregnancy, Drug resistance.
Emergence of resistance in children treated with ddI/d4T after treatment to reduce MTCT
11 September 2002. Related: Conference reports, Paediatric care.
Correlates of fatigue in HIV disease
11 September 2002. Related: Conference reports.
Optimum hydroxyurea dose determined
11 September 2002. Related: Conference reports.
Management of people with treatment experience and drug resistance
11 September 2002. Related: Conference reports, Antiretrovirals.
HIV-associated malignancies in the HAART era: flickers of hope and understanding
11 September 2002. Related: Conference reports, Cancer and HIV.
Lopinavir/r exhibits sustained virologic response in antiretroviral-naïve patients: 3-year data
11 September 2002. Related: Conference reports, Antiretrovirals.
Patients will have options regarding T-20 (enfuvirtide) injection sites
11 September 2002. Related: Conference reports, Antiretrovirals.